Leciva Announces Profits For 1995
Pharmaceutical company Leciva of the Czech Republic has revealed gross profits for 1995 of 511.3 million koruna ($18.4 million) and net profits of 310 million koruna. Total sales for the year were 4.3 billion koruna, according to the CTK news agency's Business News. 70% of turnover was generated in the domestic market, while the remaining 30% came from exports to Russia, the Ukraine, Hungary, Poland and other countries.
Leciva produces 250 medical products including antibiotics, chemotherapeutic and antidiabetes agents, analgesics, vitamins and hormones. Also, the firm has acquired licenses from leading international pharmaceutical companies such as Roussel Uclaf and SmithKline Beecham to manufacture their products in the Czech Republic.
An investment of 1 billion koruna has been made by Leciva in its business development over the past three years. It invested 452 million koruna last year, mainly in the acquisition of a quality control certificate and the installation of a computerized information system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze